RSABE [Regulatives / Guidelines]

posted by Lucas – Brazil, 2014-03-24 18:05 (4481 d 09:16 ago) – Posting: # 12694
Views: 13,522

Hello.

❝ Gives an opportunity to clarify whether


I’m struggling with this scaled BE, especially with FDA’s method. There are some papers that state that the acceptance range would be scaled based on the reference within subject variability, but the CI for the GMR would be obtained the same way as in ABE (similar to EMA’s ABEL). Others state that the criteria would not be expand the limits, but to use a “Howe method” that I haven’t quite understand yet. FDA's draft guidance from dec 2013 is not clear on that.

Can anybody help me clear that up? :confused:

Complete thread:

UA Flag
Activity
 Admin contact
23,656 posts in 4,994 threads, 1,571 registered users;
304 visitors (0 registered, 304 guests [including 17 identified bots]).
Forum time: 04:21 CEST (Europe/Vienna)

Try to learn something about everything
and everything about something.    Thomas Henry Huxley

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5